US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

10.84

-2.2400-17.13%

Pre-market: 10.80-0.0400-0.37%09:24 EDT

Volume:3.99M

Turnover:44.16M

Market Cap:393.41M

PE:-4.15

High:12.10

Open:11.90

Low:10.30

Close:13.08

52wk High:33.20

52wk Low:10.30

Shares:36.29M

Float Shares:19.98M

Volume Ratio:7.31

T/O Rate:19.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:1.42

PE(LYR):-0.97

Loading ...

Overview Company News Filings

Evommune, Inc.: to Continue Phase 2B Development of Evo756 in Migraine Prophylaxis

THOMSON REUTERS

Evommune, - Phase 2B Trial Enrolled 121 Adults; Primary and Secondary Endpoints not Met

THOMSON REUTERS

Evommune, - Evo301 to Enter Phase 2B Trial in Atopic Dermatitis in Mid-2027

THOMSON REUTERS

U.S. Stocks on the MOVE-Williams-Sonoma, Kraft Heinz, Evommune

Needham Starts Coverage on Evommune; Shares Gain

Evommune Shares up 1.7% as Needham Starts Coverage

THOMSON REUTERS

Evommune Shares up 4.2% Premarket as Needham Starts Coverage with Buy Rating

THOMSON REUTERS

Needham Initiates Evommune at Buy With $28 Price Target

MT Newswires Live

Evommune, Inc. : Needham Initiates Coverage with Buy Rating; Target Price $28

THOMSON REUTERS

Evommune Price Target Announced at $28.00/Share by Needham

U.S. Research Roundup- Intuit, MongoDB, Zscaler

Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)

Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)

RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating

MT Newswires Live

Evommune price target lowered to $29 from $30 at RBC Capital

Analysts Conflicted on These NA Names: Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY)

Evommune Posts Corporate Presentation Outlining Phase 2 Inflammation-Drug Pipeline Focusing on Evo756, Evo301

Evommune Q2 FY26 Net Loss Widens to $32.25 Million

Evommune Starts Phase 2b Trial of Evo756 for Migraine Prevention

Evommune - Top-Line Data from Phase 2B Trial Expected in 2027

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/EVMN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":10.84,"timestamp":1788984000000,"preClose":13.08,"halted":0,"volume":3986472,"hourTrading":{"tag":"盘前","latestPrice":10.8,"preClose":10.84,"latestTime":"09:24 EDT","volume":271,"amount":2940.193091,"timestamp":1789046699545,"change":-0.04,"changeRate":-0.00369,"amplitude":0.048893},"delay":0,"changeRate":-0.17125382262996944,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Pre-Mkt","change":-2.24,"latestTime":"09-10 09:25:01 EDT","open":11.9,"high":12.1,"low":10.3001,"amount":44160677.767248,"amplitude":0.137607,"askPrice":11.11,"askSize":10,"bidPrice":10,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-2.609,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":10.84,"preHourTrading":{"tag":"盘前","latestPrice":10.8,"preClose":10.84,"latestTime":"09:24 EDT","volume":271,"amount":2940.193091,"timestamp":1789046699545,"change":-0.04,"changeRate":-0.00369,"amplitude":0.048893},"postHourTrading":{"tag":"盘后","latestPrice":11.07,"preClose":10.84,"latestTime":"19:30 EDT","volume":478,"amount":5246.536,"timestamp":1788996605827,"change":0.23,"changeRate":0.021218,"amplitude":0.021218},"volumeRatio":7.30613631790136,"impliedVol":0.7207,"impliedVolPercentile":0.1875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":7.30613631790136,"shares":36292113,"dividePrice":0,"high":12.1,"amplitude":0.137607,"preClose":13.08,"low":10.3001,"week52Low":10.3001,"pbRate":"1.42","psRate":"39.34","week52High":33.2,"institutionHeld":0,"latestPrice":10.84,"committee":-0.538462,"eps":-2.609,"divideRate":0,"volume":3986472,"delay":0,"ttmEps":-2.609,"open":11.9,"prevYearClose":17.12,"fiveDayClose":12.48,"twentyDayClose":14.21,"sixtyDayClose":19.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5833,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1787803200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-09-09","current":-4.154849,"percent":0.976303,"low":-16.229076,"twenty":-12.375007,"median":-9.705573,"eighty":-6.223712,"high":-4.600344,"avg":-9.709,"sd":2.933137,"marketCap":474700838},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973},{"date":"2026-08-28","current":-5.16772,"twenty":-12.413708,"median":-9.712404,"eighty":-6.987812,"marketCap":489217683},{"date":"2026-09-04","current":-4.600344,"twenty":-12.384421,"median":-9.710846,"eighty":-6.276801,"marketCap":435505356},{"date":"2026-09-09","current":-5.014375,"twenty":-12.375007,"median":-9.705573,"eighty":-6.223712,"marketCap":474700838}],"updateTime":1789046701550},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666297370","title":"Evommune, Inc.: to Continue Phase 2B Development of Evo756 in Migraine Prophylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2666297370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666297370?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1N9QMB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666213370","title":"Evommune, - Phase 2B Trial Enrolled 121 Adults; Primary and Secondary Endpoints not Met","url":"https://stock-news.laohu8.com/highlight/detail?id=2666213370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666213370?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903780,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1N9QMB:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666037029","title":"Evommune, - Evo301 to Enter Phase 2B Trial in Atopic Dermatitis in Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666037029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666037029?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1N9QMB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662374610","title":"U.S. Stocks on the MOVE-Williams-Sonoma, Kraft Heinz, Evommune","url":"https://stock-news.laohu8.com/highlight/detail?id=2662374610","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662374610?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:40","pubTimestamp":1787766046,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Williams-Sonoma, Kraft Heinz, EvommuneAugust 26 (Reuters)-Wall Street's main indexes were subdued on Wednesday after a key inflation reading came in hotter than expected, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL6N44N0MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","BK4559","LU0006061336.USD","LU0225771236.USD","LU0070302665.USD","LU0868494617.USD","LU0162691827.USD","LU0320765489.SGD","LU0306806265.USD","LU0321505868.SGD","WSM","BK4558","BK4588","LU0321505439.SGD","BK4585","LU0942090050.USD","LU0985481810.HKD","KHC","FTXG","BK4139","LU1571399168.USD","LU0306807586.USD","BK4178","LU0170899867.USD","BK4212","EVMN","LU0072461881.USD","LU0225284248.USD","LU0211331839.USD","LU0208291251.USD","LU0868494708.USD","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745963","title":"Needham Starts Coverage on Evommune; Shares Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745963","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745963?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:32","pubTimestamp":1787761969,"startTime":"0","endTime":"0","summary":"BUZZ-Needham starts coverage on Evommune; shares gain** Shares of drug developer EvommuneEVMN.Nrise 1.7% to $14.02** Needham starts coverage on EVMN with \"buy\" rating and $28 PT** Says rating based on co's \"promising I&I pipeline, notably EVO301, an IL-18 inhibitor fusion protein, that has demonstrated proof-of-concept efficacy on par  vs. current biologics for atopic dermatitis \"** Adds \"upcoming Sept readout of the ph 2b trial in AD could generate significant shareholder value\"** EVMN has lost over 18% since its debut in November last year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N1C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662712283","title":"Evommune Shares up 1.7% as Needham Starts Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662712283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662712283?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:38","pubTimestamp":1787751482,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0NG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662785715","title":"Evommune Shares up 4.2% Premarket as Needham Starts Coverage with Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2662785715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662785715?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:42","pubTimestamp":1787744561,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N0VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715570","title":"Needham Initiates Evommune at Buy With $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715570?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:29","pubTimestamp":1787743781,"startTime":"0","endTime":"0","summary":"Evommune (EVMN) has an average rating of buy and mean price target of $29.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662713360","title":"Evommune, Inc. : Needham Initiates Coverage with Buy Rating; Target Price $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2662713360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662713360?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:06","pubTimestamp":1787742403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0D8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718146","title":"Evommune Price Target Announced at $28.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718146?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:57","pubTimestamp":1787741820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662989427","title":"U.S. Research Roundup- Intuit, MongoDB, Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2662989427","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662989427?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:57","pubTimestamp":1787727427,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Intuit, MongoDB, ZscalerAug 26 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Intuit, MongoDB and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N0EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOX","AXGN","JAZZ","AFRM","DELL","NKE","SNOU","FROG","MRNX","AMR","GTLB","FDTX","MRNA","ASB","INTU","DKS","MDB","NEOG","APP","CHWY","LHX","MRVL","SMOG","GPN","SNOW","FIVE","CAKE","NCNO","OLLI","SOXY","CPRT","FSLR","MRVU","RBRK","EVMN","ADIG","WCLD","EPAM","LSCC","AMRX","FIS","CNR","FRNW","STYL","GDDY","AIS","CTEC","SMTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659150197","title":"Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659150197?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:40","pubTimestamp":1786628434,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on BitGo Holdings, Inc. Class A (BTGO) and Evommune, Inc. (EVMN...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-bitgo-holdings-inc-class-a-btgo-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-bitgo-holdings-inc-class-a-btgo-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BTGO","BK4127","EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931856","title":"Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931856","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931856?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:45","pubTimestamp":1786365951,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Evommune, Inc. today and set a price target of $22.00. Clark-Gartner covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646812","title":"RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646812?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:46","pubTimestamp":1786106799,"startTime":"0","endTime":"0","summary":"Evommune (EVMN) has an average rating of buy and mean price target of $32.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657453676","title":"Evommune price target lowered to $29 from $30 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2657453676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657453676?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:21","pubTimestamp":1786105261,"startTime":"0","endTime":"0","summary":"RBC Capital lowered the firm’s price target on Evommune (EVMN) to $29 from $30 and keeps an Outperform rating on the shares. Despite the stock’s re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-29-from-30-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-29-from-30-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657066615","title":"Analysts Conflicted on These NA Names: Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657066615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657066615?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:40","pubTimestamp":1786092008,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY). Fis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-fiserv-fisv-evommune-inc-evmn-and-waystar-holding-corp-way-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-fiserv-fisv-evommune-inc-evmn-and-waystar-holding-corp-way-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WAY","BK4167","LU0208291251.USD","LU0354030511.USD","LU1046421795.USD","LU1861220207.SGD","LU1823568750.SGD","LU1169590202.USD","BK4227","FISV","BK4139","LU0354030438.USD","LU0070302665.USD","LU0648000940.SGD","BK4106","BK4585","LU0130102774.USD","LU1923622291.USD","BK4141","LU2125909759.SGD","LU1861217088.USD","FINX","LU1201861165.SGD","BK4588","LU0980610538.SGD","EVMN","LU1815336091.USD","LU0130103400.USD","LU1169589451.USD","LU0320765489.SGD","LU1201861249.SGD","NA","LU0757428866.USD","LU2125909916.SGD","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669650","title":"Evommune Posts Corporate Presentation Outlining Phase 2 Inflammation-Drug Pipeline Focusing on Evo756, Evo301","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669650?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:11","pubTimestamp":1786054289,"startTime":"0","endTime":"0","summary":"Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301Evommune outlined two Phase 2 programs in chronic inflammatory diseases, led by EVO756 in a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLcdShYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650670","title":"Evommune Q2 FY26 Net Loss Widens to $32.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650670","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650670?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047455,"startTime":"0","endTime":"0","summary":"Evommune Q2 FY26 net loss widens to $32.25 millionEvommune posted a Q2 net loss of USD 32.25 million, widening from USD 13.57 million a year earlier.R&D expense rose 34.49% to USD 26.41 million, while","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1n2hZk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872837","title":"Evommune Starts Phase 2b Trial of Evo756 for Migraine Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872837?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:01","pubTimestamp":1785412874,"startTime":"0","endTime":"0","summary":"Evommune starts Phase 2b trial of EVO756 for migraine preventionEvommune launched a Phase 2b trial of oral MRGPRX2 inhibitor EVO756 for migraine prevention, dosing the first patient.Top-line results h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDLrzbqn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874090","title":"Evommune - Top-Line Data from Phase 2B Trial Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874090?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA8LHQNZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":106,"code":"91000000","status":"200"}]}}